Evotec stock reports a 19.2 percent first half revenue decline

Published on 10/04/2026 at 18:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock posted EUR 300.1 million in H1 2026 revenue, down 19.2 percent year over year. Q3 results are scheduled for November 5, 2026.

Schwarzweiß-Dokumentarfoto einer Forscherin am Mikroskop in einem biotechnologischen Labor — Schwarzweiß-Reportagefoto zeigt Laborarbeit im Biotech-Sektor, passend zu Evotec SE, ISIN DE0005664809, dokumentarischer Forschungsalltag, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) was last at EUR 2.920 on Xetra on October 2, 2026, while first-half revenue fell 19.2 percent year over year to EUR 300.1 million. The result puts the companys cost-cutting program and pipeline execution at the center of the next reporting checkpoint.

Revenue pressure remains visible

According to Stock World on September 23, 2026, Evotec generated EUR 300.1 million in revenue in the first half of 2026, compared with the prior-year period, while adjusted EBITDA reached negative EUR 42.7 million. The same report said the Horizon transformation program targets EUR 75 million in savings.

The second quarter contributed EUR 143.479 million in revenue and a net loss of EUR 46.649 million, according to the latest standardized quarterly figures for Q2 2026. That combination matters because the savings program must offset weaker sales conversion and restore operating leverage before the company can rebuild confidence.

Analyst target stays above market

Borse Express reported on September 26, 2026, that Berenberg retained a Hold rating and a EUR 3.60 price target. Against the EUR 2.920 Xetra price, that target stands 23.3 percent above the market level.

The target leaves room for a recovery, but the operating figures define the condition. Evotec needs measurable progress in revenue conversion and cost control for the valuation gap to become more than an analyst assumption.

November brings the next test

Stock World reported that Evotec plans to publish its third-quarter 2026 results on November 5, 2026. The release will offer the next quantified check on whether Horizon is changing the cost base while the core business remains under pressure.

Evotec stock stays under pressure

Evotec stock was last at EUR 2.920 on Xetra on October 2, 2026, down 3.57 percent from the previous session. The company had a market capitalization of EUR 517.8 million as of October 2, 2026.